Fmr LLC boosted its stake in Quanterix Co. (NASDAQ:QTRX – Free Report) by 112.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,242 shares of the company’s stock after acquiring an additional 16,020 shares during the period. Fmr LLC owned 0.08% of Quanterix worth $392,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Baillie Gifford & Co. grew its stake in Quanterix by 1.6% during the second quarter. Baillie Gifford & Co. now owns 633,460 shares of the company’s stock worth $8,368,000 after purchasing an additional 10,105 shares during the period. Easterly Investment Partners LLC grew its position in shares of Quanterix by 779.9% during the 2nd quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock worth $9,151,000 after buying an additional 614,012 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Quanterix by 14.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 132,100 shares of the company’s stock valued at $1,745,000 after acquiring an additional 16,395 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Quanterix by 11.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 14,261 shares of the company’s stock valued at $188,000 after acquiring an additional 1,417 shares during the period. Finally, Picton Mahoney Asset Management boosted its stake in Quanterix by 91.7% during the second quarter. Picton Mahoney Asset Management now owns 165,076 shares of the company’s stock worth $2,180,000 after acquiring an additional 78,984 shares in the last quarter. Institutional investors own 86.48% of the company’s stock.
Analysts Set New Price Targets
Separately, TD Cowen lifted their price target on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.
Quanterix Stock Down 3.3 %
Shares of QTRX stock opened at $9.99 on Friday. The firm has a market cap of $383.41 million, a P/E ratio of -9.51 and a beta of 1.30. The company has a 50 day moving average of $12.45 and a 200-day moving average of $13.14. Quanterix Co. has a 12-month low of $9.94 and a 12-month high of $29.70.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
Further Reading
- Five stocks we like better than Quanterix
- What is a Low P/E Ratio and What Does it Tell Investors?
- Micron Stock Under $100: Seize the AI-Driven Upside
- What Investors Need to Know About Upcoming IPOs
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Best Stocks Under $10.00
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRX – Free Report).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.